Education
About Us
Working with TipRanks
Follow Us
Rohto Pharmaceutical Co (RPHCF)
:RPHCF
RESEARCH TOOLSreports
Total Valuation
Rohto Pharmaceutical Co has a market cap or net worth of $3.26B. The enterprise value is $538.09B.
Market Cap$3.26B
Enterprise Value$538.09B
Share Statistics
Rohto Pharmaceutical Co has 236,178,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding236,178,310
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rohto Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 11.64%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)11.64%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee37.31M
Profits Per Employee4.26M
Employee Count7,259
Asset Turnover0.78
Inventory Turnover2.43
Valuation Ratios
The current PE Ratio of Rohto Pharmaceutical Co is 22.15. Rohto Pharmaceutical Co’s PEG ratio is 2.26.
PE Ratio22.15
PS Ratio0.00
PB Ratio2.20
Price to Fair Value2.78
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio2.26
Income Statement
In the last 12 months, Rohto Pharmaceutical Co had revenue of 270.84B and earned 30.94B in profits. Earnings per share was 135.60.
Revenue270.84B
Gross Profit157.29B
Operating Income40.05B
Pretax Income41.52B
Net Income30.94B
EBITDA50.40B
Earnings Per Share (EPS)135.60
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Rohto Pharmaceutical Co pays an annual dividend of $0.118, resulting in a dividend yield of 1.69%
Dividend Per Share$0.118
Dividend Yield1.69%
Payout Ratio12.49%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.17
52-Week Price Change-25.97%
50-Day Moving Average15.63
200-Day Moving Average18.62
Relative Strength Index (RSI)35.53
Average Volume (3m)0.00
Important Dates
Rohto Pharmaceutical Co upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Rohto Pharmaceutical Co as a current ratio of 2.47, with Debt / Equity ratio of 15.15%
Current Ratio2.47
Quick Ratio1.93
Debt to Market Cap0.02
Net Debt to EBITDA-1.56
Interest Coverage Ratio204.33
Taxes
In the past 12 months, Rohto Pharmaceutical Co has paid 10.12B in taxes.
Income Tax10.12B
Effective Tax Rate0.24
Enterprise Valuation
Rohto Pharmaceutical Co EV to EBITDA ratio is 12.04, with an EV/FCF ratio of 23.95.
EV to Sales2.24
EV to EBITDA12.04
EV to Free Cash Flow23.95
EV to Operating Cash Flow17.71
Balance Sheet
Rohto Pharmaceutical Co has $61.71B in cash and marketable securities with ¥38.81B in debt, giving a net cash position of -$22.91B billion.
Cash & Marketable Securities$61.71B
Total Debt¥38.81B
Net Cash-$22.91B
Net Cash Per Share-$96.99
Tangible Book Value Per Share$1.04K
Margins
Gross margin is 57.23%, with operating margin of 14.79%, and net profit margin of 11.42%.
Gross Margin57.23%
Operating Margin14.79%
Pretax Margin15.33%
Net Profit Margin11.42%
EBITDA Margin18.61%
EBIT Margin15.40%
Analyst Forecast
The average price target for Rohto Pharmaceutical Co is $17.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.65
Price Target Upside24.91% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―